Elisabeth Digifico

640 total citations
12 papers, 486 citations indexed

About

Elisabeth Digifico is a scholar working on Immunology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Elisabeth Digifico has authored 12 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 5 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Elisabeth Digifico's work include Immune cells in cancer (9 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Phagocytosis and Immune Regulation (4 papers). Elisabeth Digifico is often cited by papers focused on Immune cells in cancer (9 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Phagocytosis and Immune Regulation (4 papers). Elisabeth Digifico collaborates with scholars based in Italy, Spain and United Kingdom. Elisabeth Digifico's co-authors include Paola Allavena, Cristina Belgiovine, Fernando Torres, Akihiro Maeda, Alberto Mantovani, Marco Erreni, Aldo Ummarino, Marı́a José Alonso, Clément Anfray and Manuela Liguori and has published in prestigious journals such as International Journal of Molecular Sciences, Frontiers in Immunology and European Journal of Immunology.

In The Last Decade

Elisabeth Digifico

12 papers receiving 485 citations

Peers

Elisabeth Digifico
Elisabeth Digifico
Citations per year, relative to Elisabeth Digifico Elisabeth Digifico (= 1×) peers Aldo Ummarino

Countries citing papers authored by Elisabeth Digifico

Since Specialization
Citations

This map shows the geographic impact of Elisabeth Digifico's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Digifico with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Digifico more than expected).

Fields of papers citing papers by Elisabeth Digifico

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Digifico. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Digifico. The network helps show where Elisabeth Digifico may publish in the future.

Co-authorship network of co-authors of Elisabeth Digifico

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Digifico. A scholar is included among the top collaborators of Elisabeth Digifico based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Digifico. Elisabeth Digifico is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Belgiovine, Cristina, Elisabeth Digifico, Marco Erreni, et al.. (2025). Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB. Journal of Translational Medicine. 23(1). 454–454. 1 indexed citations
2.
Digifico, Elisabeth, Marco Erreni, Laura Mannarino, et al.. (2023). Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma. Frontiers in Immunology. 14. 1116430–1116430. 3 indexed citations
3.
Allavena, Paola, Cristina Belgiovine, Elisabeth Digifico, Roberta Frapolli, & Maurizio D’Incalci. (2022). Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment. Frontiers in Oncology. 12. 851790–851790. 19 indexed citations
4.
Anfray, Clément, Francesco Mainini, Elisabeth Digifico, et al.. (2021). Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity. Journal for ImmunoTherapy of Cancer. 9(9). e002408–e002408. 67 indexed citations
5.
Belgiovine, Cristina, Roberta Frapolli, Manuela Liguori, et al.. (2021). Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy. European Journal of Immunology. 51(11). 2677–2686. 23 indexed citations
6.
Allavena, Paola, Elisabeth Digifico, & Cristina Belgiovine. (2021). Macrophages and cancer stem cells: a malevolent alliance. Molecular Medicine. 27(1). 121–121. 54 indexed citations
7.
Digifico, Elisabeth, et al.. (2021). The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset. International Journal of Molecular Sciences. 22(3). 1224–1224. 7 indexed citations
8.
Liguori, Manuela, Elisabeth Digifico, Federico Colombo, et al.. (2020). The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33. Cellular and Molecular Immunology. 18(3). 711–722. 89 indexed citations
9.
Digifico, Elisabeth, Marco Erreni, Federico Colombo, et al.. (2020). Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice. Cancers. 12(8). 2136–2136. 6 indexed citations
10.
Belgiovine, Cristina, Elisabeth Digifico, Clément Anfray, Aldo Ummarino, & Fernando Torres. (2020). Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing. Journal of Clinical Medicine. 9(10). 3226–3226. 60 indexed citations
11.
Maeda, Akihiro, Elisabeth Digifico, Fernando Torres, Alberto Mantovani, & Paola Allavena. (2019). Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor‐conditioned macrophages. European Journal of Immunology. 49(5). 801–811. 48 indexed citations
12.
Torres, Fernando, Elisabeth Digifico, Akihiro Maeda, et al.. (2017). Targeting tumor associated macrophages: The new challenge for nanomedicine. Seminars in Immunology. 34. 103–113. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026